BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kazankov K, Jørgensen SMD, Thomsen KL, Møller HJ, Vilstrup H, George J, Schuppan D, Grønbæk H. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 2019;16:145-59. [DOI: 10.1038/s41575-018-0082-x] [Cited by in Crossref: 177] [Cited by in F6Publishing: 185] [Article Influence: 44.3] [Reference Citation Analysis]
Number Citing Articles
1 Ni Y, Zhuge F, Nagashimada M, Nagata N, Xu L, Yamamoto S, Fuke N, Ushida Y, Suganuma H, Kaneko S, Ota T. Lycopene prevents the progression of lipotoxicity-induced nonalcoholic steatohepatitis by decreasing oxidative stress in mice. Free Radic Biol Med 2020;152:571-82. [PMID: 31790829 DOI: 10.1016/j.freeradbiomed.2019.11.036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
2 Yan T, Yan N, Wang P, Xia Y, Hao H, Wang G, Gonzalez FJ. Herbal drug discovery for the treatment of nonalcoholic fatty liver disease. Acta Pharm Sin B 2020;10:3-18. [PMID: 31993304 DOI: 10.1016/j.apsb.2019.11.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
3 Yao Q, Li S, Li X, Wang F, Tu C. Myricetin Modulates Macrophage Polarization and Mitigates Liver Inflammation and Fibrosis in a Murine Model of Nonalcoholic Steatohepatitis. Front Med 2020;7:71. [DOI: 10.3389/fmed.2020.00071] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
4 Beyaz Coşkun A, Sağdiçoğlu Celep AG. Therapeutic modulation methods of gut microbiota and gut-liver axis. Crit Rev Food Sci Nutr 2021;:1-11. [PMID: 33749411 DOI: 10.1080/10408398.2021.1902263] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Yoshio S, Kanto T. Macrophages as a source of fibrosis biomarkers for non-alcoholic fatty liver disease. Immunol Med 2021;44:175-86. [PMID: 33444517 DOI: 10.1080/25785826.2020.1868664] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Remmerie A, Martens L, Scott CL. Macrophage Subsets in Obesity, Aligning the Liver and Adipose Tissue. Front Endocrinol (Lausanne) 2020;11:259. [PMID: 32411096 DOI: 10.3389/fendo.2020.00259] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
7 De Muynck K, Vanderborght B, Van Vlierberghe H, Devisscher L. The Gut-Liver Axis in Chronic Liver Disease: A Macrophage Perspective. Cells 2021;10:2959. [PMID: 34831182 DOI: 10.3390/cells10112959] [Reference Citation Analysis]
8 Gao F, Zheng KI, Yan HD, Sun QF, Pan KH, Wang TY, Chen YP, Targher G, Byrne CD, George J, Zheng MH. Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019. Front Endocrinol (Lausanne) 2021;12:604100. [PMID: 33763027 DOI: 10.3389/fendo.2021.604100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Jeon JW, Choi N, Lee SH, Sung JH. Three-tissue microphysiological system for studying inflammatory responses in gut-liver Axis. Biomed Microdevices 2020;22:65. [PMID: 32915326 DOI: 10.1007/s10544-020-00519-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Gwag T, Reddy Mooli RG, Li D, Lee S, Lee EY, Wang S. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease. JHEP Rep 2021;3:100193. [PMID: 33294831 DOI: 10.1016/j.jhepr.2020.100193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
11 Madill-Thomsen KS, Abouljoud M, Bhati C, Ciszek M, Durlik M, Feng S, Foroncewicz B, Francis I, Grąt M, Jurczyk K, Klintmalm G, Krasnodębski M, McCaughan G, Miquel R, Montano-Loza A, Moonka D, Mucha K, Myślak M, Pączek L, Perkowska-Ptasińska A, Piecha G, Reichman T, Sanchez-Fueyo A, Tronina O, Wawrzynowicz-Syczewska M, Więcek A, Zieniewicz K, Halloran PF. The molecular phenotypes of injury, steatohepatitis, and fibrosis in liver transplant biopsies in the INTERLIVER study. Am J Transplant 2021. [PMID: 34780106 DOI: 10.1111/ajt.16890] [Reference Citation Analysis]
12 Xu D, Tian Y, Xia Q, Ke B. The cGAS-STING Pathway: Novel Perspectives in Liver Diseases. Front Immunol 2021;12:682736. [PMID: 33995425 DOI: 10.3389/fimmu.2021.682736] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Liang S, Ji L, Kang L, Hu X. Metabolic regulation of innate immunity. Advances in Immunology in China - Part B. Elsevier; 2020. pp. 129-57. [DOI: 10.1016/bs.ai.2019.11.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Ma Y, Lee G, Heo S, Roh Y. Oxidative Stress Is a Key Modulator in the Development of Nonalcoholic Fatty Liver Disease. Antioxidants 2022;11:91. [DOI: 10.3390/antiox11010091] [Reference Citation Analysis]
15 Moreno-Fernandez ME, Miraldi ER, Divanovic S. Not Chopped Liver-A Careful, Fate-Mapping Study of Macrophages in NASH. Cell Metab 2020;32:328-30. [PMID: 32877688 DOI: 10.1016/j.cmet.2020.08.005] [Reference Citation Analysis]
16 Svop Jensen V, Fledelius C, Max Wulff E, Lykkesfeldt J, Hvid H. Temporal Development of Dyslipidemia and Nonalcoholic Fatty Liver Disease (NAFLD) in Syrian Hamsters Fed a High-Fat, High-Fructose, High-Cholesterol Diet. Nutrients 2021;13:604. [PMID: 33673227 DOI: 10.3390/nu13020604] [Reference Citation Analysis]
17 Li H, Yu XH, Ou X, Ouyang XP, Tang CK. Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis. Prog Lipid Res 2021;83:101109. [PMID: 34097928 DOI: 10.1016/j.plipres.2021.101109] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Dong X, Feng Y, Xu D, Zhang M, Wen X, Zhao W, Hu Q, Zhang Q, Fu H, Ping J. Targeting macrophagic 17β-HSD7 by fenretinide for the treatment of nonalcoholic fatty liver disease. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.04.003] [Reference Citation Analysis]
19 Tang G, Zhang L, Tao J, Wei Z. Effect of Nigella sativa in the treatment of nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. Phytother Res 2021;35:4183-93. [PMID: 33728708 DOI: 10.1002/ptr.7080] [Reference Citation Analysis]
20 Thompson WL, Takebe T. Generation of multi-cellular human liver organoids from pluripotent stem cells. Methods Cell Biol 2020;159:47-68. [PMID: 32586449 DOI: 10.1016/bs.mcb.2020.03.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Zhang Q, Wang J, Huang F, Yao Y, Xu L. Leptin induces NAFLD progression through infiltrated CD8+ T lymphocytes mediating pyroptotic-like cell death of hepatocytes and macrophages. Dig Liver Dis 2021;53:598-605. [PMID: 33172809 DOI: 10.1016/j.dld.2020.10.025] [Reference Citation Analysis]
22 Luo Y, Guo J, Jia W, Wu M, Yin F, Niu G, Shih DQ, Targan SR, Zhang X. TNF-Like Ligand 1 Aberrance Aggravates Nonalcoholic Steatohepatitis via M1 Macrophage Polarization. Oxid Med Cell Longev 2021;2021:3877617. [PMID: 35003513 DOI: 10.1155/2021/3877617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Pan L, Huang P, Xie X, Xu J, Guo D, Jiang Y. Metabolic associated fatty liver disease increases the severity of COVID-19: A meta-analysis. Dig Liver Dis. 2021;53:153-157. [PMID: 33011088 DOI: 10.1016/j.dld.2020.09.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
24 Luci C, Bourinet M, Leclère PS, Anty R, Gual P. Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies. Front Endocrinol (Lausanne) 2020;11:597648. [PMID: 33384662 DOI: 10.3389/fendo.2020.597648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
25 Lucia Appleton S, Navarro-Orcajada S, Martínez-Navarro FJ, Caldera F, López-Nicolás JM, Trotta F, Matencio A. Cyclodextrins as Anti-inflammatory Agents: Basis, Drugs and Perspectives. Biomolecules 2021;11:1384. [PMID: 34572597 DOI: 10.3390/biom11091384] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Buyco DG, Martin J, Jeon S, Hooks R, Lin C, Carr R. Experimental models of metabolic and alcoholic fatty liver disease. World J Gastroenterol 2021; 27(1): 1-18 [PMID: 33505147 DOI: 10.3748/wjg.v27.i1.1] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
27 Pilling D, Karhadkar TR, Gomer RH. A CD209 ligand and a sialidase inhibitor differentially modulate adipose tissue and liver macrophage populations and steatosis in mice on the Methionine and Choline-Deficient (MCD) diet. PLoS One 2020;15:e0244762. [PMID: 33378413 DOI: 10.1371/journal.pone.0244762] [Reference Citation Analysis]
28 Rosso C, Kazankov K, Younes R, Esmaili S, Marietti M, Sacco M, Carli F, Gaggini M, Salomone F, Møller HJ, Abate ML, Vilstrup H, Gastaldelli A, George J, Grønbæk H, Bugianesi E. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. Journal of Hepatology 2019;71:1012-21. [DOI: 10.1016/j.jhep.2019.06.031] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 17.3] [Reference Citation Analysis]
29 Xin X, Jin Y, Wang X, Cai B, An Z, Hu YY, Feng Q. A Combination of Geniposide and Chlorogenic Acid Combination Ameliorates Nonalcoholic Steatohepatitis in Mice by Inhibiting Kupffer Cell Activation. Biomed Res Int 2021;2021:6615881. [PMID: 34095305 DOI: 10.1155/2021/6615881] [Reference Citation Analysis]
30 Chen S, Guo H, Xie M, Zhou C, Zheng M. Neutrophil: An emerging player in the occurrence and progression of metabolic associated fatty liver disease. Int Immunopharmacol 2021;97:107609. [PMID: 33887577 DOI: 10.1016/j.intimp.2021.107609] [Reference Citation Analysis]
31 Wculek SK, Dunphy G, Heras-Murillo I, Mastrangelo A, Sancho D. Metabolism of tissue macrophages in homeostasis and pathology. Cell Mol Immunol 2021. [PMID: 34876704 DOI: 10.1038/s41423-021-00791-9] [Reference Citation Analysis]
32 Huang E, Peng N, Xiao F, Hu D, Wang X, Lu L. The Roles of Immune Cells in the Pathogenesis of Fibrosis. Int J Mol Sci 2020;21:E5203. [PMID: 32708044 DOI: 10.3390/ijms21155203] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
33 Daemen S, Gainullina A, Kalugotla G, He L, Chan MM, Beals JW, Liss KH, Klein S, Feldstein AE, Finck BN, Artyomov MN, Schilling JD. Dynamic Shifts in the Composition of Resident and Recruited Macrophages Influence Tissue Remodeling in NASH. Cell Rep 2021;34:108626. [PMID: 33440159 DOI: 10.1016/j.celrep.2020.108626] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
34 Ji Y, Yin W, Liang Y, Sun L, Yin Y, Zhang W. Anti-Inflammatory and Anti-Oxidative Activity of Indole-3-Acetic Acid Involves Induction of HO-1 and Neutralization of Free Radicals in RAW264.7 Cells. Int J Mol Sci 2020;21:E1579. [PMID: 32106625 DOI: 10.3390/ijms21051579] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
35 Dai S, Liu F, Qin Z, Zhang J, Chen J, Ding WX, Feng D, Ji Y, Qin X. Kupffer cells promote T-cell hepatitis by producing CXCL10 and limiting liver sinusoidal endothelial cell permeability. Theranostics 2020;10:7163-77. [PMID: 32641985 DOI: 10.7150/thno.44960] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
36 Xu Y, Yang X, Bian H, Xia M. Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management. Lipids Health Dis 2021;20:126. [PMID: 34602072 DOI: 10.1186/s12944-021-01564-z] [Reference Citation Analysis]
37 Arroyave-Ospina JC, Wu Z, Geng Y, Moshage H. Role of Oxidative Stress in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Implications for Prevention and Therapy. Antioxidants (Basel) 2021;10:174. [PMID: 33530432 DOI: 10.3390/antiox10020174] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 15.0] [Reference Citation Analysis]
38 Hu J, Ying H, Yao J, Yang L, Jin W, Ma H, Li L, Zhao Y. Micronized Palmitoylethanolamide Ameliorates Methionine- and Choline-Deficient Diet-Induced Nonalcoholic Steatohepatitis via Inhibiting Inflammation and Restoring Autophagy. Front Pharmacol 2021;12:744483. [PMID: 34712137 DOI: 10.3389/fphar.2021.744483] [Reference Citation Analysis]
39 Zhang C, Yang M, Ericsson AC. Function of Macrophages in Disease: Current Understanding on Molecular Mechanisms. Front Immunol 2021;12:620510. [PMID: 33763066 DOI: 10.3389/fimmu.2021.620510] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
40 Govaere O, Petersen SK, Martinez-lopez N, Wouters J, Van Haele M, Mancina RM, Jamialahmadi O, Bilkei-gorzo O, Lassen PB, Darlay R, Peltier J, Palmer JM, Younes R, Tiniakos D, Aithal GP, Allison M, Vacca M, Göransson M, Berlinguer-palmini R, Clark JE, Drinnan MJ, Yki-järvinen H, Dufour J, Ekstedt M, Francque S, Petta S, Bugianesi E, Schattenberg JM, Day CP, Cordell HJ, Topal B, Clément K, Romeo S, Ratziu V, Roskams T, Daly AK, Anstee QM, Trost M, Härtlova A. Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease. Journal of Hepatology 2021. [DOI: 10.1016/j.jhep.2021.12.012] [Reference Citation Analysis]
41 Li X, Yuan B, Lu M, Wang Y, Ding N, Liu C, Gao M, Yao Z, Zhang S, Zhao Y, Xie L, Chen Z. The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression. Nat Commun 2021;12:7213. [PMID: 34893641 DOI: 10.1038/s41467-021-27539-3] [Reference Citation Analysis]
42 Patel SJ, Liu N, Piaker S, Gulko A, Andrade ML, Heyward FD, Sermersheim T, Edinger N, Srinivasan H, Emont MP, Westcott GP, Luther J, Chung RT, Yan S, Kumari M, Thomas R, Deleye Y, Tchernof A, White PJ, Baselli GA, Meroni M, De Jesus DF, Ahmad R, Kulkarni RN, Valenti L, Tsai L, Rosen ED. Hepatic IRF3 fuels dysglycemia in obesity through direct regulation of Ppp2r1b. Sci Transl Med 2022;14:eabh3831. [PMID: 35320000 DOI: 10.1126/scitranslmed.abh3831] [Reference Citation Analysis]
43 Yang L, Dong C, Yang J, Yang L, Chang N, Qi C, Li L. MicroRNA-26b-5p Inhibits Mouse Liver Fibrogenesis and Angiogenesis by Targeting PDGF Receptor-Beta. Mol Ther Nucleic Acids. 2019;16:206-217. [PMID: 30901579 DOI: 10.1016/j.omtn.2019.02.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
44 Wang Y, Wang G, Bai J, Zhao N, Wang Q, Zhou R, Li G, Hu C, Li X, Tao K, Xia Z, Wang G. Role of Indole-3-Acetic Acid in NAFLD Amelioration After Sleeve Gastrectomy. OBES SURG 2021;31:3040-52. [DOI: 10.1007/s11695-021-05321-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Barreby E, Chen P, Aouadi M. Macrophage functional diversity in NAFLD — more than inflammation. Nat Rev Endocrinol. [DOI: 10.1038/s41574-022-00675-6] [Reference Citation Analysis]
46 Zheng C, Sui B, Zhang X, Hu J, Chen J, Liu J, Wu D, Ye Q, Xiang L, Qiu X, Liu S, Deng Z, Zhou J, Liu S, Shi S, Jin Y. Apoptotic vesicles restore liver macrophage homeostasis to counteract type 2 diabetes. J Extracell Vesicles 2021;10:e12109. [PMID: 34084287 DOI: 10.1002/jev2.12109] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
47 Rashed ZE, Grasselli E, Khalifeh H, Canesi L, Demori I. Brown-Algae Polysaccharides as Active Constituents against Nonalcoholic Fatty Liver Disease. Planta Med 2020. [PMID: 33142346 DOI: 10.1055/a-1273-3159] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
48 Sim JH, Sherman JB, Stanley TL, Corey KE, Fitch KV, Looby SE, Robinson JA, Lu MT, Burdo TH, Lo J. Pro-Inflammatory Interleukin-18 is Associated with Hepatic Steatosis and Elevated Liver Enzymes in People with HIV Monoinfection. AIDS Res Hum Retroviruses 2021;37:385-90. [PMID: 33323025 DOI: 10.1089/AID.2020.0177] [Reference Citation Analysis]
49 Zhao P, Han SN, Arumugam S, Yousaf MN, Qin Y, Jiang JX, Torok NJ, Chen Y, Mankash MS, Liu J, Li J, Iwakiri Y, Ouyang X. Digoxin improves steatohepatitis with differential involvement of liver cell subsets in mice through inhibition of PKM2 transactivation. Am J Physiol Gastrointest Liver Physiol 2019;317:G387-97. [PMID: 31411894 DOI: 10.1152/ajpgi.00054.2019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
50 Li P, Chen X, Dong M, Luo J, Lu S, Chen M, Zhang Y, Zhou H, Jiang H. Gut inflammation exacerbates high-fat diet induced steatosis by suppressing VLDL-TG secretion through HNF4α pathway. Free Radic Biol Med 2021;172:459-69. [PMID: 34186207 DOI: 10.1016/j.freeradbiomed.2021.06.027] [Reference Citation Analysis]
51 Lu S, Wang Y, Liu J. TNF-α signaling in non-alcoholic steatohepatitis and targeted therapies. J Genet Genomics 2021:S1673-8527(21)00337-4. [PMID: 34757037 DOI: 10.1016/j.jgg.2021.09.009] [Reference Citation Analysis]
52 Wei X, Hou W, Liang J, Fang P, Dou B, Wang Z, Sai J, Xu T, Ma C, Zhang Q, Cheng F, Wang X, Wang Q. Network Pharmacology-Based Analysis on the Potential Biological Mechanisms of Sinisan Against Non-Alcoholic Fatty Liver Disease. Front Pharmacol 2021;12:693701. [PMID: 34512330 DOI: 10.3389/fphar.2021.693701] [Reference Citation Analysis]
53 Hu C, Li X, Sui Y, Chen Y, Zhao Y, Yang Y, Zhou Q, Ni H, Sun L, Gan W, Li J, Liu Y. Dicer deletion in hepatocytes promotes macrophages M1 polarization through dysregulated miR-192-3p/IGF2 in non-alcoholic steatohepatitis and hepatocellular carcinoma. Cancer Gene Ther 2022. [PMID: 35165388 DOI: 10.1038/s41417-022-00432-x] [Reference Citation Analysis]
54 Chen XY, Wang C, Huang YZ, Zhang LL. Nonalcoholic fatty liver disease shows significant sex dimorphism. World J Clin Cases 2022; 10(5): 1457-1472 [DOI: 10.12998/wjcc.v10.i5.1457] [Reference Citation Analysis]
55 Moore MP, Cunningham RP, Davis RAH, Deemer SE, Roberts BM, Plaisance EP, Rector RS. A dietary ketone ester mitigates histological outcomes of NAFLD and markers of fibrosis in high-fat diet fed mice. Am J Physiol Gastrointest Liver Physiol 2021;320:G564-72. [PMID: 33501889 DOI: 10.1152/ajpgi.00259.2020] [Reference Citation Analysis]
56 Chen W, Yang A, Jia J, Popov YV, Schuppan D, You H. Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis. Hepatology 2020;72:729-41. [DOI: 10.1002/hep.31236] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
57 Wu C, Cheng D, Peng Y, Li Y, Fu C, Wang Y, Fu L, Peng S, Ni X. Hepatic BRD4 Is Upregulated in Liver Fibrosis of Various Etiologies and Positively Correlated to Fibrotic Severity. Front Med (Lausanne) 2021;8:683506. [PMID: 34336890 DOI: 10.3389/fmed.2021.683506] [Reference Citation Analysis]
58 Jones AE, Divakaruni AS. Macrophage activation as an archetype of mitochondrial repurposing. Mol Aspects Med 2020;71:100838. [PMID: 31954522 DOI: 10.1016/j.mam.2019.100838] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
59 Sato K, Kennedy L, Liangpunsakul S, Kusumanchi P, Yang Z, Meng F, Glaser S, Francis H, Alpini G. Intercellular Communication between Hepatic Cells in Liver Diseases. Int J Mol Sci 2019;20:E2180. [PMID: 31052525 DOI: 10.3390/ijms20092180] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
60 Thibaut R, Gage MC, Pineda-Torra I, Chabrier G, Venteclef N, Alzaid F. Liver macrophages and inflammation in physiology and physiopathology of non-alcoholic fatty liver disease. FEBS J 2021. [PMID: 33860630 DOI: 10.1111/febs.15877] [Reference Citation Analysis]
61 Qu W, Ma T, Cai J, Zhang X, Zhang P, She Z, Wan F, Li H. Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies. Front Med (Lausanne) 2021;8:761538. [PMID: 34746195 DOI: 10.3389/fmed.2021.761538] [Reference Citation Analysis]
62 Kadono K, Kageyama S, Nakamura K, Hirao H, Ito T, Kojima H, Dery KJ, Li X, Kupiec-Weglinski JW. Myeloid ikaros-SIRT1 signaling axis regulates hepatic inflammation and pyroptosis in ischemia-stressed mouse and human liver. J Hepatol 2021:S0168-8278(21)02235-2. [PMID: 34871625 DOI: 10.1016/j.jhep.2021.11.026] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Hu J, Wang H, Li X, Liu Y, Mi Y, Kong H, Xi D, Yan W, Luo X, Ning Q, Wang X. Fibrinogen-like protein 2 aggravates nonalcoholic steatohepatitis via interaction with TLR4, eliciting inflammation in macrophages and inducing hepatic lipid metabolism disorder. Theranostics 2020;10:9702-20. [PMID: 32863955 DOI: 10.7150/thno.44297] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
64 Hwang S, Yun H, Moon S, Cho YE, Gao B. Role of Neutrophils in the Pathogenesis of Nonalcoholic Steatohepatitis. Front Endocrinol (Lausanne) 2021;12:751802. [PMID: 34707573 DOI: 10.3389/fendo.2021.751802] [Reference Citation Analysis]
65 Fang X, Xu S, Zhang Y, Xu J, Huang Z, Liu W, Wang S, Yen K, Zhang W. Asxl1 C-terminal mutation perturbs neutrophil differentiation in zebrafish. Leukemia 2021;35:2299-310. [PMID: 33483612 DOI: 10.1038/s41375-021-01121-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Franchitto A, Carpino G, Alisi A, De Peppo F, Overi D, De Stefanis C, Romito I, De Vito R, Caccamo R, Sonia B, Alessandra S, Mosca A, Alterio A, Onori P, Gaudio E, Nobili V. The Contribution of the Adipose Tissue-Liver Axis in Pediatric Patients with Nonalcoholic Fatty Liver Disease after Laparoscopic Sleeve Gastrectomy. The Journal of Pediatrics 2020;216:117-127.e2. [DOI: 10.1016/j.jpeds.2019.07.037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
67 Ni Y, Ni L, Zhuge F, Fu Z. The Gut Microbiota and Its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease. Mol Nutr Food Res 2020;64:e2000375. [PMID: 32738185 DOI: 10.1002/mnfr.202000375] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
68 Li S, Han S, Jin K, Yu T, Chen H, Zhou X, Tan Z, Zhang G. SOCS2 Suppresses Inflammation and Apoptosis during NASH Progression through Limiting NF-κB Activation in Macrophages. Int J Biol Sci 2021;17:4165-75. [PMID: 34803490 DOI: 10.7150/ijbs.63889] [Reference Citation Analysis]
69 Bence KK, Birnbaum MJ. Metabolic drivers of non-alcoholic fatty liver disease. Mol Metab 2021;50:101143. [PMID: 33346069 DOI: 10.1016/j.molmet.2020.101143] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
70 Menini S, Iacobini C, Vitale M, Pugliese G. The Inflammasome in Chronic Complications of Diabetes and Related Metabolic Disorders. Cells 2020;9:E1812. [PMID: 32751658 DOI: 10.3390/cells9081812] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
71 Oates JR, McKell MC, Moreno-Fernandez ME, Damen MSMA, Deepe GS Jr, Qualls JE, Divanovic S. Macrophage Function in the Pathogenesis of Non-alcoholic Fatty Liver Disease: The Mac Attack. Front Immunol 2019;10:2893. [PMID: 31921154 DOI: 10.3389/fimmu.2019.02893] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
72 Cho HJ, Kim HJ, Lee K, Lasli S, Ung A, Hoffman T, Nasiri R, Bandaru P, Ahadian S, Dokmeci MR, Lee J, Khademhosseini A. Bioengineered Multicellular Liver Microtissues for Modeling Advanced Hepatic Fibrosis Driven Through Non-Alcoholic Fatty Liver Disease. Small 2021;17:e2007425. [PMID: 33690979 DOI: 10.1002/smll.202007425] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Kim E, Um H, Park J, Jung JW, Kim JE, Lee H, Shin EA, Pinanga Y, Lee H, Nam SH, Lee JW. TM4SF5-dependent crosstalk between hepatocytes and macrophages to reprogram the inflammatory environment. Cell Rep 2021;37:110018. [PMID: 34788612 DOI: 10.1016/j.celrep.2021.110018] [Reference Citation Analysis]
74 Bajgar A, Krejčová G, Doležal T. Polarization of Macrophages in Insects: Opening Gates for Immuno-Metabolic Research. Front Cell Dev Biol 2021;9:629238. [PMID: 33659253 DOI: 10.3389/fcell.2021.629238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Sun QJ, Cai LY, Jian J, Cui YL, Huang CK, Liu SQ, Lu JL, Wang W, Zeng X, Zhong L. The Role of Bone Morphogenetic Protein 9 in Nonalcoholic Fatty Liver Disease in Mice. Front Pharmacol 2020;11:605967. [PMID: 33603666 DOI: 10.3389/fphar.2020.605967] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 He X, Hu Y, Liu W, Zhu G, Zhang R, You J, Shao Y, Li Y, Zhang Z, Cui J, He Y, Ge G, Yang H. Deciphering the Effective Constituents and Mechanisms of Portulaca oleracea L. for Treating NASH via Integrating Bioinformatics Analysis and Experimental Pharmacology. Front Pharmacol 2022;12:818227. [DOI: 10.3389/fphar.2021.818227] [Reference Citation Analysis]
77 Jian C, Xu Y, Ma X, Shen Y, Wang Y, Bao Y. Neck Circumference is an Effective Supplement for Nonalcoholic Fatty Liver Disease Screening in a Community-Based Population. Int J Endocrinol 2020;2020:7982107. [PMID: 32508918 DOI: 10.1155/2020/7982107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
78 Schippers M, Post E, Eichhorn I, Langeland J, Beljaars L, Malo MS, Hodin RA, Millán JL, Popov Y, Schuppan D, Poelstra K. Phosphate Groups in the Lipid A Moiety Determine the Effects of LPS on Hepatic Stellate Cells: A Role for LPS-Dephosphorylating Activity in Liver Fibrosis. Cells 2020;9:E2708. [PMID: 33348845 DOI: 10.3390/cells9122708] [Reference Citation Analysis]
79 Xia MF, Bian H, Gao X. NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment. Front Pharmacol. 2019;10:877. [PMID: 31447675 DOI: 10.3389/fphar.2019.00877] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
80 Moreno-Fernandez ME, Giles DA, Oates JR, Chan CC, Damen MSMA, Doll JR, Stankiewicz TE, Chen X, Chetal K, Karns R, Weirauch MT, Romick-Rosendale L, Xanthakos SA, Sheridan R, Szabo S, Shah AS, Helmrath MA, Inge TH, Deshmukh H, Salomonis N, Divanovic S. PKM2-dependent metabolic skewing of hepatic Th17 cells regulates pathogenesis of non-alcoholic fatty liver disease. Cell Metab 2021;33:1187-1204.e9. [PMID: 34004162 DOI: 10.1016/j.cmet.2021.04.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
81 Guo Q, Furuta K, Lucien F, Gutierrez Sanchez LH, Hirsova P, Krishnan A, Kabashima A, Pavelko KD, Madden B, Alhuwaish H, Gao Y, Revzin A, Ibrahim SH. Integrin β1-enriched extracellular vesicles mediate monocyte adhesion and promote liver inflammation in murine NASH. J Hepatol 2019;71:1193-205. [PMID: 31433301 DOI: 10.1016/j.jhep.2019.07.019] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 13.7] [Reference Citation Analysis]
82 Zhang X, Thompkins-Johns A, Ziober A, Zhang PJ, Furth EE. Hepatic Macrophage Types Cluster with Disease Etiology in Chronic Liver Disease and Differ Compared to Normal Liver: Implications for Their Biologic and Diagnostic Role. Int J Surg Pathol 2022;:10668969221099630. [PMID: 35521912 DOI: 10.1177/10668969221099630] [Reference Citation Analysis]
83 Bellanti F, Vendemiale G. Coronavirus disease 2019 and non-alcoholic fatty liver disease. World J Hepatol 2021; 13(9): 969-978 [PMID: 34630869 DOI: 10.4254/wjh.v13.i9.969] [Reference Citation Analysis]
84 Della Torre S. Non-alcoholic Fatty Liver Disease as a Canonical Example of Metabolic Inflammatory-Based Liver Disease Showing a Sex-Specific Prevalence: Relevance of Estrogen Signaling. Front Endocrinol (Lausanne) 2020;11:572490. [PMID: 33071979 DOI: 10.3389/fendo.2020.572490] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
85 Xu F, Guo M, Huang W, Feng L, Zhu J, Luo K, Gao J, Zheng B, Kong LD, Pang T, Wu X, Xu Q. Annexin A5 regulates hepatic macrophage polarization via directly targeting PKM2 and ameliorates NASH. Redox Biol 2020;36:101634. [PMID: 32863213 DOI: 10.1016/j.redox.2020.101634] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
86 Zhou J, Sun L, Liu L, Jia Y, Han Y, Shao J, Wang J, Wang Y, Yu L, Yan Z. Hepatic macrophage targeted siRNA lipid nanoparticles treat non-alcoholic steatohepatitis. Journal of Controlled Release 2022. [DOI: 10.1016/j.jconrel.2022.01.038] [Reference Citation Analysis]
87 Batty MJ, Chabrier G, Sheridan A, Gage MC. Metabolic Hormones Modulate Macrophage Inflammatory Responses. Cancers (Basel) 2021;13:4661. [PMID: 34572888 DOI: 10.3390/cancers13184661] [Reference Citation Analysis]
88 Baeza-Raja B, Goodyear A, Liu X, Lam K, Yamamoto L, Li Y, Dodson GS, Takeuchi T, Kisseleva T, Brenner DA, Dabbagh K. Pharmacological inhibition of P2RX7 ameliorates liver injury by reducing inflammation and fibrosis. PLoS One 2020;15:e0234038. [PMID: 32492075 DOI: 10.1371/journal.pone.0234038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
89 Biagioli M, Fiorucci S. Bile acid activated receptors: Integrating immune and metabolic regulation in non-alcoholic fatty liver disease. Liver Research 2021;5:119-41. [DOI: 10.1016/j.livres.2021.08.003] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
90 Santos-laso A, Gutiérrez-larrañaga M, Alonso-peña M, Medina JM, Iruzubieta P, Arias-loste MT, López-hoyos M, Crespo J. Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets. Biomedicines 2022;10:46. [DOI: 10.3390/biomedicines10010046] [Reference Citation Analysis]
91 Zhu LY, Liu C, Li ZR, Niu C, Wu J. NLRP3 deficiency did not attenuate NASH development under high fat calorie diet plus high fructose and glucose in drinking water. Lab Invest 2021;101:588-99. [PMID: 33526807 DOI: 10.1038/s41374-021-00535-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Liu B, Xiang L, Ji J, Liu W, Chen Y, Xia M, Liu Y, Liu W, Zhu P, Jin Y, Han Y, Lu J, Li X, Zheng M, Lu Y. Sparcl1 promotes nonalcoholic steatohepatitis progression in mice through upregulation of CCL2. J Clin Invest 2021;131:e144801. [PMID: 34651580 DOI: 10.1172/JCI144801] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
93 Mandala A, Janssen RC, Palle S, Short KR, Friedman JE. Pediatric Non-Alcoholic Fatty Liver Disease: Nutritional Origins and Potential Molecular Mechanisms. Nutrients 2020;12:E3166. [PMID: 33081177 DOI: 10.3390/nu12103166] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
94 Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA, Ouatu A, Floria M. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD).J Diabetes Res. 2020;2020:3920196. [PMID: 32832560 DOI: 10.1155/2020/3920196] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
95 Wen X, Shi C, Yang L, Zeng X, Lin X, Huang J, Li Y, Zhuang R, Zhu H, Guo Z, Zhang X. A radioiodinated FR-β-targeted tracer with improved pharmacokinetics through modification with an albumin binder for imaging of macrophages in AS and NAFL. Eur J Nucl Med Mol Imaging 2021. [PMID: 34155537 DOI: 10.1007/s00259-021-05447-4] [Reference Citation Analysis]
96 Luo Y, Lu H, Peng D, Ruan X, Eugene Chen Y, Guo Y. Liver-humanized mice: A translational strategy to study metabolic disorders. J Cell Physiol 2021. [PMID: 34661916 DOI: 10.1002/jcp.30610] [Reference Citation Analysis]
97 Yang H, Park T, Park D, Kang M. Trovafloxacin drives inflammation-associated drug-induced adverse hepatic reaction through changing macrophage polarization. Toxicology in Vitro 2022. [DOI: 10.1016/j.tiv.2022.105374] [Reference Citation Analysis]
98 Lee YA, Friedman SL. Inflammatory and fibrotic mechanisms in NAFLD-Implications for new treatment strategies. J Intern Med 2021. [PMID: 34564899 DOI: 10.1111/joim.13380] [Reference Citation Analysis]
99 Ling B, Lee J, Maresca D, Lee-Gosselin A, Malounda D, Swift MB, Shapiro MG. Biomolecular Ultrasound Imaging of Phagolysosomal Function. ACS Nano 2020;14:12210-21. [PMID: 32902951 DOI: 10.1021/acsnano.0c05912] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
100 Bai L, Kong M, Duan Z, Liu S, Zheng S, Chen Y. M2-like macrophages exert hepatoprotection in acute-on-chronic liver failure through inhibiting necroptosis-S100A9-necroinflammation axis. Cell Death Dis 2021;12:93. [PMID: 33462187 DOI: 10.1038/s41419-020-03378-w] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
101 Knudsen C, Neyrinck AM, Leyrolle Q, Baldin P, Leclercq S, Rodriguez J, Beaumont M, Cani PD, Bindels LB, Lanthier N, Delzenne NM. Hepatoprotective Effects of Indole, a Gut Microbial Metabolite, in Leptin-Deficient Obese Mice. J Nutr 2021;151:1507-16. [PMID: 33693866 DOI: 10.1093/jn/nxab032] [Reference Citation Analysis]
102 Kang H, Lee Y, Kim MB, Hu S, Jang H, Park YK, Lee JY. The loss of histone deacetylase 4 in macrophages exacerbates hepatic and adipose tissue inflammation in male but not in female mice with diet-induced non-alcoholic steatohepatitis. J Pathol 2021. [PMID: 34374436 DOI: 10.1002/path.5758] [Reference Citation Analysis]
103 Yen IC, Tu QW, Chang TC, Lin PH, Li YF, Lee SY. 4-Acetylantroquinonol B ameliorates nonalcoholic steatohepatitis by suppression of ER stress and NLRP3 inflammasome activation. Biomed Pharmacother 2021;138:111504. [PMID: 33773468 DOI: 10.1016/j.biopha.2021.111504] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
104 Jensen VS, Fledelius C, Zachodnik C, Damgaard J, Nygaard H, Tornqvist KS, Kirk RK, Viuff BM, Wulff EM, Lykkesfeldt J, Hvid H. Insulin treatment improves liver histopathology and decreases expression of inflammatory and fibrogenic genes in a hyperglycemic, dyslipidemic hamster model of NAFLD. J Transl Med 2021;19:80. [PMID: 33596938 DOI: 10.1186/s12967-021-02729-1] [Reference Citation Analysis]
105 Phatruengdet T, Khuemjun P, Intakhad J, Krunchanuchat S, Chariyakornkul A, Wongpoomchai R, Pilapong C. Pharmacokinetic/Pharmacodynamic Determinations of Iron-tannic Molecular Nanoparticles with its Implication in MR Imaging and Enhancement of Liver Clearance. Nanotheranostics 2022;6:195-204. [PMID: 34976594 DOI: 10.7150/ntno.63310] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Martínez-Chantar ML, Delgado TC, Beraza N. Revisiting the Role of Natural Killer Cells in Non-Alcoholic Fatty Liver Disease. Front Immunol 2021;12:640869. [PMID: 33679803 DOI: 10.3389/fimmu.2021.640869] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
107 Díaz-Bulnes P, Saiz ML, López-Larrea C, Rodríguez RM. Crosstalk Between Hypoxia and ER Stress Response: A Key Regulator of Macrophage Polarization. Front Immunol 2019;10:2951. [PMID: 31998288 DOI: 10.3389/fimmu.2019.02951] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
108 Cheung A, Ahmed A. Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: A Review of Links and Risks. Clin Exp Gastroenterol 2021;14:457-65. [PMID: 34819740 DOI: 10.2147/CEG.S226130] [Reference Citation Analysis]
109 Zhao C, Medeiros TX, Sové RJ, Annex BH, Popel AS. A data-driven computational model enables integrative and mechanistic characterization of dynamic macrophage polarization. iScience 2021;24:102112. [PMID: 33659877 DOI: 10.1016/j.isci.2021.102112] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
110 Kazankov K, Bojsen-Møller KN, Møller HJ, Madsbad S, Grønbaek H. Macrophage activation marker sCD163 is associated with liver injury and hepatic insulin resistance in obese patients before and after Roux-en-Y gastric bypass. Physiol Rep 2022;10:e15157. [PMID: 35040267 DOI: 10.14814/phy2.15157] [Reference Citation Analysis]
111 Osorio-Conles Ó, Vega-Beyhart A, Ibarzabal A, Balibrea JM, Graupera I, Rimola J, Vidal J, de Hollanda A. A Distinctive NAFLD Signature in Adipose Tissue from Women with Severe Obesity. Int J Mol Sci 2021;22:10541. [PMID: 34638880 DOI: 10.3390/ijms221910541] [Reference Citation Analysis]
112 Wang R, Yao L, Lin X, Hu X, Wang L. Exploring the potential mechanism of Rhodomyrtus tomentosa (Ait.) Hassk fruit phenolic rich extract on ameliorating nonalcoholic fatty liver disease by integration of transcriptomics and metabolomics profiling. Food Res Int 2022;151:110824. [PMID: 34980375 DOI: 10.1016/j.foodres.2021.110824] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Caballano-infantes E, García-garcía A, Lopez-gomez C, Cueto A, Robles-diaz M, Ortega-alonso A, Martín-reyes F, Alvarez-alvarez I, Arranz-salas I, Ruiz-cabello F, Lucena IM, García-fuentes E, Andrade RJ, García-cortes M. Differential iNKT and T Cells Activation in Non-Alcoholic Fatty Liver Disease and Drug-Induced Liver Injury. Biomedicines 2022;10:55. [DOI: 10.3390/biomedicines10010055] [Reference Citation Analysis]
114 Gupta H, Min B, Ganesan R, Gebru YA, Sharma SP, Park E, Won S, Jeong J, Lee S, Cha M, Kwon G, Jeong M, Hyun J, Eom J, Park H, Yoon S, Choi M, Kim D, Suk K. Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role. Biomedicines 2022;10:550. [DOI: 10.3390/biomedicines10030550] [Reference Citation Analysis]
115 Han J, Zhang X. Complement Component C3: A Novel Biomarker Participating in the Pathogenesis of Non-alcoholic Fatty Liver Disease. Front Med (Lausanne) 2021;8:653293. [PMID: 34395461 DOI: 10.3389/fmed.2021.653293] [Reference Citation Analysis]
116 Jin K, Liu Y, Shi Y, Zhang H, Sun Y, Zhangyuan G, Wang F, Yu W, Wang J, Tao X, Chen X, Zhang W, Sun B. PTPROt aggravates inflammation by enhancing NF-κB activation in liver macrophages during nonalcoholic steatohepatitis. Theranostics 2020;10:5290-304. [PMID: 32373213 DOI: 10.7150/thno.42658] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
117 Yan S, Tian S, Meng Z, Teng M, Sun W, Jia M, Zhou Z, Bi S, Zhu W. Exposure to nitenpyram during pregnancy causes colonic mucosal damage and non-alcoholic steatohepatitis in mouse offspring: The role of gut microbiota. Environ Pollut 2021;271:116306. [PMID: 33360580 DOI: 10.1016/j.envpol.2020.116306] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
118 Schwabe RF, Tabas I, Pajvani UB. Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis. Gastroenterology 2020;158:1913-28. [PMID: 32044315 DOI: 10.1053/j.gastro.2019.11.311] [Cited by in Crossref: 47] [Cited by in F6Publishing: 53] [Article Influence: 23.5] [Reference Citation Analysis]
119 Wang C, Ma C, Gong L, Guo Y, Fu K, Zhang Y, Zhou H, Li Y. Macrophage Polarization and Its Role in Liver Disease. Front Immunol 2021;12:803037. [PMID: 34970275 DOI: 10.3389/fimmu.2021.803037] [Reference Citation Analysis]
120 Escutia-Gutiérrez R, Rodríguez-Sanabria JS, Monraz-Méndez CA, García-Bañuelos J, Santos-García A, Sandoval-Rodríguez A, Armendáriz-Borunda J. Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH. Sci Rep 2021;11:11709. [PMID: 34083664 DOI: 10.1038/s41598-021-91187-2] [Reference Citation Analysis]
121 Francque S, Szabo G, Abdelmalek MF, Byrne CD, Cusi K, Dufour J, Roden M, Sacks F, Tacke F. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. Nat Rev Gastroenterol Hepatol 2021;18:24-39. [DOI: 10.1038/s41575-020-00366-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 11.0] [Reference Citation Analysis]
122 Omori S, Wang TW, Johmura Y, Kanai T, Nakano Y, Kido T, Susaki EA, Nakajima T, Shichino S, Ueha S, Ozawa M, Yokote K, Kumamoto S, Nishiyama A, Sakamoto T, Yamaguchi K, Hatakeyama S, Shimizu E, Katayama K, Yamada Y, Yamazaki S, Iwasaki K, Miyoshi C, Funato H, Yanagisawa M, Ueno H, Imoto S, Furukawa Y, Yoshida N, Matsushima K, Ueda HR, Miyajima A, Nakanishi M. Generation of a p16 Reporter Mouse and Its Use to Characterize and Target p16high Cells In Vivo. Cell Metab 2020;32:814-828.e6. [PMID: 32949498 DOI: 10.1016/j.cmet.2020.09.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
123 Xia Y, Lei C, Yang D, Luo H. Construction and validation of a bronchoalveolar lavage cell-associated gene signature for prognosis prediction in idiopathic pulmonary fibrosis. Int Immunopharmacol 2021;92:107369. [PMID: 33493738 DOI: 10.1016/j.intimp.2021.107369] [Reference Citation Analysis]
124 Sakamoto Y, Yoshio S, Doi H, Kawai H, Shimagaki T, Mori T, Matsuda M, Aoki Y, Osawa Y, Yoshida Y, Arai T, Itokawa N, Ito T, Seko Y, Yamaguchi K, Itoh Y, Mise Y, Saiura A, Taketomi A, Kanto T. Serum soluble sialic acid‐binding immunoglobulin‐like lectin‐7 concentration as an indicator of liver macrophage activation and advanced fibrosis in patients with non‐alcoholic fatty liver disease. Hepatol Res 2020;50:466-77. [DOI: 10.1111/hepr.13464] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
125 Tuzer C, Sertbas Y, Duman E, Komoglu S, Kan O, Ay S, Yigit A, Sertbas M, Okuroglu N, Ozen B, Dalbeler A, Ozdemir A. The role of mean platelet volume in nonalcoholic fatty liver disease without cardiovascular comorbidities, obesity and diabetes mellitus. Eur J Gastroenterol Hepatol 2021;33:1222-8. [PMID: 34397640 DOI: 10.1097/MEG.0000000000002189] [Reference Citation Analysis]
126 Nagashimada M, Honda M. Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics. Int J Mol Sci 2021;22:8008. [PMID: 34360773 DOI: 10.3390/ijms22158008] [Reference Citation Analysis]
127 Lin L, Jian J, Song CY, Chen F, Ding K, Xie WF, Hu PF. SHP-1 ameliorates nonalcoholic steatohepatitis by inhibiting proinflammatory cytokine production. FEBS Lett 2020;594:2965-74. [PMID: 32619269 DOI: 10.1002/1873-3468.13879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
128 Kim K, Kim KH. Targeting of Secretory Proteins as a Therapeutic Strategy for Treatment of Nonalcoholic Steatohepatitis (NASH). Int J Mol Sci 2020;21:E2296. [PMID: 32225108 DOI: 10.3390/ijms21072296] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
129 Yen IC, Lin JC, Chen Y, Tu QW, Lee SY. Antrodia Cinnamomea Attenuates Non-Alcoholic Steatohepatitis by Suppressing NLRP3 Inflammasome Activation In Vitro and In Vivo. Am J Chin Med 2020;48:1859-74. [PMID: 33308101 DOI: 10.1142/S0192415X20500937] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
130 Bloomer SA, Moyer ED. Hepatic macrophage accumulation with aging: cause for concern? Am J Physiol Gastrointest Liver Physiol 2021;320:G496-505. [PMID: 33470190 DOI: 10.1152/ajpgi.00286.2020] [Reference Citation Analysis]
131 Sovaila S, Purcarea A, Gheonea D, Ionescu S, Ciurea T. Cellular Interactions in the Human Fatty Liver. J Med Life 2019;12:338-40. [PMID: 32025251 DOI: 10.25122/jml-2019-1010] [Reference Citation Analysis]
132 Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 2021;184:2537-64. [PMID: 33989548 DOI: 10.1016/j.cell.2021.04.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
133 Liu B, Deng X, Jiang Q, Li G, Zhang J, Zhang N, Xin S, Xu K. Scoparone alleviates inflammation, apoptosis and fibrosis of non-alcoholic steatohepatitis by suppressing the TLR4/NF-κB signaling pathway in mice. International Immunopharmacology 2019;75:105797. [DOI: 10.1016/j.intimp.2019.105797] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
134 Torre P, Motta BM, Sciorio R, Masarone M, Persico M. Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System. Front Med (Lausanne) 2021;8:781567. [PMID: 34957156 DOI: 10.3389/fmed.2021.781567] [Reference Citation Analysis]
135 Somm E, Montandon SA, Loizides-Mangold U, Gaïa N, Lazarevic V, De Vito C, Perroud E, Bochaton-Piallat ML, Dibner C, Schrenzel J, Jornayvaz FR. The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet. Transl Res 2021;227:75-88. [PMID: 32711187 DOI: 10.1016/j.trsl.2020.07.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
136 Jiang X, Zhang F, Ji X, Dong F, Yu H, Xue M, Qiu Y, Yang F, Hu X, Bao Z. Lipid-injured hepatocytes release sOPN to improve macrophage migration via CD44 engagement and pFak-NFκB signaling. Cytokine 2021;142:155474. [PMID: 33647584 DOI: 10.1016/j.cyto.2021.155474] [Reference Citation Analysis]
137 Evangelakos I, Schwinge D, Worthmann A, John C, Roeder N, Pertzborn P, Behrens J, Schramm C, Scheja L, Heeren J. Oxysterol 7-α Hydroxylase (CYP7B1) Attenuates Metabolic-Associated Fatty Liver Disease in Mice at Thermoneutrality. Cells 2021;10:2656. [PMID: 34685636 DOI: 10.3390/cells10102656] [Reference Citation Analysis]
138 Gay MD, Safronenka A, Cao H, Liu FH, Malchiodi ZX, Tucker RD, Kroemer A, Shivapurkar N, Smith JP. Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular Cancer. Cancer Prev Res (Phila) 2021;14:17-30. [PMID: 33115780 DOI: 10.1158/1940-6207.CAPR-20-0220] [Reference Citation Analysis]
139 Pafili K, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol Metab 2021;50:101122. [PMID: 33220492 DOI: 10.1016/j.molmet.2020.101122] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
140 Sun G, Zhao X, Li M, Zhang C, Jin H, Li C, Liu L, Wang Y, Shi W, Tian D, Xu H, Tian Y, Wu Y, Liu K, Zhang Z, Zhang D. CD4 derived double negative T cells prevent the development and progression of nonalcoholic steatohepatitis. Nat Commun 2021;12:650. [PMID: 33510172 DOI: 10.1038/s41467-021-20941-x] [Reference Citation Analysis]
141 Prasun P, Ginevic I, Oishi K. Mitochondrial dysfunction in nonalcoholic fatty liver disease and alcohol related liver disease. Transl Gastroenterol Hepatol 2021;6:4. [PMID: 33437892 DOI: 10.21037/tgh-20-125] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
142 Pfefferlé M, Ingoglia G, Schaer CA, Yalamanoglu A, Buzzi R, Dubach IL, Tan G, López-Cano EY, Schulthess N, Hansen K, Humar R, Schaer DJ, Vallelian F. Hemolysis transforms liver macrophages into antiinflammatory erythrophagocytes. J Clin Invest 2020;130:5576-90. [PMID: 32663195 DOI: 10.1172/JCI137282] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
143 Ji Y, Gao Y, Chen H, Yin Y, Zhang W. Indole-3-Acetic Acid Alleviates Nonalcoholic Fatty Liver Disease in Mice via Attenuation of Hepatic Lipogenesis, and Oxidative and Inflammatory Stress. Nutrients 2019;11:E2062. [PMID: 31484323 DOI: 10.3390/nu11092062] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
144 Liang XY, Hong FF, Yang SL. Astragaloside IV Alleviates Liver Inflammation, Oxidative Stress and Apoptosis to Protect Against Experimental Non-Alcoholic Fatty Liver Disease. Diabetes Metab Syndr Obes 2021;14:1871-83. [PMID: 33953586 DOI: 10.2147/DMSO.S304817] [Reference Citation Analysis]
145 Rom O, Xu G, Guo Y, Zhu Y, Wang H, Zhang J, Fan Y, Liang W, Lu H, Liu Y, Aviram M, Liu Z, Kim S, Liu W, Wang X, Chen YE, Villacorta L. Nitro-fatty acids protect against steatosis and fibrosis during development of nonalcoholic fatty liver disease in mice. EBioMedicine 2019;41:62-72. [PMID: 30772307 DOI: 10.1016/j.ebiom.2019.02.019] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
146 Dou L, Shi X, He X, Gao Y. Macrophage Phenotype and Function in Liver Disorder. Front Immunol 2019;10:3112. [PMID: 32047496 DOI: 10.3389/fimmu.2019.03112] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
147 Zhu B, Chan SL, Li J, Li K, Wu H, Cui K, Chen H. Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment. Front Cardiovasc Med 2021;8:742382. [PMID: 34557535 DOI: 10.3389/fcvm.2021.742382] [Reference Citation Analysis]
148 Gan Z, Zhang M, Xie D, Wu X, Hong C, Fu J, Fan L, Wang S, Han S. Glycinergic Signaling in Macrophages and Its Application in Macrophage-Associated Diseases. Front Immunol 2021;12:762564. [PMID: 34675940 DOI: 10.3389/fimmu.2021.762564] [Reference Citation Analysis]
149 Guillot A, Tacke F. Liver Macrophages: Old Dogmas and New Insights. Hepatol Commun 2019;3:730-43. [PMID: 31168508 DOI: 10.1002/hep4.1356] [Cited by in Crossref: 106] [Cited by in F6Publishing: 105] [Article Influence: 35.3] [Reference Citation Analysis]
150 Doub JB, Ng VY, Johnson AJ, Slomka M, Fackler J, Horne B, Brownstein MJ, Henry M, Malagon F, Biswas B. Salvage Bacteriophage Therapy for a Chronic MRSA Prosthetic Joint Infection. Antibiotics (Basel) 2020;9:E241. [PMID: 32397354 DOI: 10.3390/antibiotics9050241] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
151 Della Torre S. Beyond the X Factor: Relevance of Sex Hormones in NAFLD Pathophysiology. Cells 2021;10:2502. [PMID: 34572151 DOI: 10.3390/cells10092502] [Reference Citation Analysis]
152 Toita R, Shimizu E, Kang J. Unique cellular interaction of macrophage-targeted liposomes potentiates anti-inflammatory activity. Chem Commun 2020;56:8253-6. [DOI: 10.1039/d0cc03320k] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
153 Chen J, Vitetta L, Henson JD, Hall S. Intestinal Dysbiosis, the Tryptophan Pathway and Nonalcoholic Steatohepatitis. Int J�Tryptophan�Res 2022;15:117864692110705. [DOI: 10.1177/11786469211070533] [Reference Citation Analysis]
154 Kaps L, Huppertsberg A, Choteschovsky N, Klefenz A, Durak F, Schrörs B, Diken M, Eichler E, Rosigkeit S, Schmitt S, Leps C, Schulze A, Foerster F, Bockamp E, De Geest BG, Koynov K, Räder HJ, Tenzer S, Marini F, Schuppan D, Nuhn L. pH-degradable, bisphosphonate-loaded nanogels attenuate liver fibrosis by repolarization of M2-type macrophages. Proc Natl Acad Sci U S A 2022;119:e2122310119. [PMID: 35290110 DOI: 10.1073/pnas.2122310119] [Reference Citation Analysis]
155 Stinnett G, Taheri N, Villanova J, Bohloul A, Guo X, Esposito EP, Xiao Z, Stueber D, Avendano C, Decuzzi P, Pautler RG, Colvin VL. 2D Gadolinium Oxide Nanoplates as T1 Magnetic Resonance Imaging Contrast Agents. Adv Healthc Mater 2021;10:e2001780. [PMID: 33882196 DOI: 10.1002/adhm.202001780] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
156 Tan M, Mosaoa R, Graham GT, Kasprzyk-Pawelec A, Gadre S, Parasido E, Catalina-Rodriguez O, Foley P, Giaccone G, Cheema A, Kallakury B, Albanese C, Yi C, Avantaggiati ML. Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH. Cell Death Differ 2020;27:2143-57. [PMID: 31959914 DOI: 10.1038/s41418-020-0491-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
157 Liu M, Huang Q, Zhu Y, Chen L, Li Y, Gong Z, Ai K. Harnessing reactive oxygen/nitrogen species and inflammation: Nanodrugs for liver injury. Materials Today Bio 2022. [DOI: 10.1016/j.mtbio.2022.100215] [Reference Citation Analysis]
158 Xia MF, Chen LY, Wu L, Ma H, Li Q, Aleteng Q, Hu Y, He WY, Gao J, Lin HD, Gao X. The PNPLA3 rs738409 C>G variant influences the association between low skeletal muscle mass and NAFLD: the Shanghai Changfeng Study. Aliment Pharmacol Ther 2019;50:684-95. [PMID: 31250467 DOI: 10.1111/apt.15372] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
159 Cai Q, Gan C, Tang C, Wu H, Gao J. Mechanism and Therapeutic Opportunities of Histone Modifications in Chronic Liver Disease. Front Pharmacol 2021;12:784591. [PMID: 34887768 DOI: 10.3389/fphar.2021.784591] [Reference Citation Analysis]
160 Overi D, Carpino G, Franchitto A, Onori P, Gaudio E. Hepatocyte Injury and Hepatic Stem Cell Niche in the Progression of Non-Alcoholic Steatohepatitis. Cells 2020;9:E590. [PMID: 32131439 DOI: 10.3390/cells9030590] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
161 Jiang DX, Zhang JB, Li MT, Lin SZ, Wang YQ, Chen YW, Fan JG. Prolyl endopeptidase gene disruption attenuates high fat diet-induced nonalcoholic fatty liver disease in mice by improving hepatic steatosis and inflammation. Ann Transl Med 2020;8:218. [PMID: 32309365 DOI: 10.21037/atm.2020.01.14] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
162 Fiorucci S, Zampella A, Ricci P, Distrutti E, Biagioli M. Immunomodulatory functions of FXR. Mol Cell Endocrinol 2022;551:111650. [PMID: 35472625 DOI: 10.1016/j.mce.2022.111650] [Reference Citation Analysis]
163 Santoso CS, Li Z, Lal S, Yuan S, Gan KA, Agosto LM, Liu X, Pro SC, Sewell JA, Henderson A, Atianand MK, Fuxman Bass JI. Comprehensive mapping of the human cytokine gene regulatory network. Nucleic Acids Res 2020;48:12055-73. [PMID: 33179750 DOI: 10.1093/nar/gkaa1055] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
164 Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, Ferrucci L, Gilroy DW, Fasano A, Miller GW, Miller AH, Mantovani A, Weyand CM, Barzilai N, Goronzy JJ, Rando TA, Effros RB, Lucia A, Kleinstreuer N, Slavich GM. Chronic inflammation in the etiology of disease across the life span. Nat Med 2019;25:1822-32. [PMID: 31806905 DOI: 10.1038/s41591-019-0675-0] [Cited by in Crossref: 429] [Cited by in F6Publishing: 446] [Article Influence: 143.0] [Reference Citation Analysis]
165 Hou J, Zhang J, Cui P, Zhou Y, Liu C, Wu X, Ji Y, Wang S, Cheng B, Ye H, Shu L, Zhang K, Wang D, Xu J, Shu Q, Colonna M, Fang X. TREM2 sustains macrophage-hepatocyte metabolic coordination in nonalcoholic fatty liver disease and sepsis. J Clin Invest 2021;131:135197. [PMID: 33586673 DOI: 10.1172/JCI135197] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
166 Ni Y, Ni L, Zhuge F, Xu L, Fu Z, Ota T. Adipose Tissue Macrophage Phenotypes and Characteristics: The Key to Insulin Resistance in Obesity and Metabolic Disorders. Obesity (Silver Spring) 2020;28:225-34. [PMID: 31903735 DOI: 10.1002/oby.22674] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 14.0] [Reference Citation Analysis]
167 Liou C, Wu S, Shen S, Chen L, Chen Y, Huang W. Acacetin Protects against Non-Alcoholic Fatty Liver Disease by Regulating Lipid Accumulation and Inflammation in Mice. IJMS 2022;23:4687. [DOI: 10.3390/ijms23094687] [Reference Citation Analysis]
168 Srdić M, Ovčina I, Fotschki B, Haros CM, Llopis JML. C. quinoa and S. hispanica L. Seeds Provide Immunonutritional Agonists to Selectively Polarize Macrophages. Cells 2020;9:E593. [PMID: 32131465 DOI: 10.3390/cells9030593] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
169 Xu QY, Li H, Cao HX, Pan Q, Fan JG. APOC3 rs2070667 Associates with Serum Triglyceride Profile and Hepatic Inflammation in Nonalcoholic Fatty Liver Disease. Biomed Res Int 2020;2020:8869674. [PMID: 33294458 DOI: 10.1155/2020/8869674] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
170 van der Heide D, Weiskirchen R, Bansal R. Therapeutic Targeting of Hepatic Macrophages for the Treatment of Liver Diseases. Front Immunol 2019;10:2852. [PMID: 31849997 DOI: 10.3389/fimmu.2019.02852] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 13.0] [Reference Citation Analysis]
171 Jiang Q, Li Q, Liu B, Li G, Riedemann G, Gaitantzi H, Breitkopf-Heinlein K, Zeng A, Ding H, Xu K. BMP9 promotes methionine- and choline-deficient diet-induced nonalcoholic steatohepatitis in non-obese mice by enhancing NF-κB dependent macrophage polarization. Int Immunopharmacol 2021;96:107591. [PMID: 33812253 DOI: 10.1016/j.intimp.2021.107591] [Reference Citation Analysis]
172 Albadawy R, Agwa SHA, Khairy E, Saad M, El Touchy N, Othman M, El Kassas M, Matboli M. Circulatory Endothelin 1-Regulating RNAs Panel: Promising Biomarkers for Non-Invasive NAFLD/NASH Diagnosis and Stratification: Clinical and Molecular Pilot Study. Genes (Basel) 2021;12:1813. [PMID: 34828420 DOI: 10.3390/genes12111813] [Reference Citation Analysis]
173 Ströbel S, Kostadinova R, Fiaschetti-Egli K, Rupp J, Bieri M, Pawlowska A, Busler D, Hofstetter T, Sanchez K, Grepper S, Thoma E. A 3D primary human cell-based in vitro model of non-alcoholic steatohepatitis for efficacy testing of clinical drug candidates. Sci Rep 2021;11:22765. [PMID: 34815444 DOI: 10.1038/s41598-021-01951-7] [Reference Citation Analysis]
174 Li H, Zhou Y, Wang H, Zhang M, Qiu P, Zhang M, Zhang R, Zhao Q, Liu J. Crosstalk Between Liver Macrophages and Surrounding Cells in Nonalcoholic Steatohepatitis. Front Immunol 2020;11:1169. [PMID: 32670278 DOI: 10.3389/fimmu.2020.01169] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
175 Hintikka J, Lensu S, Mäkinen E, Karvinen S, Honkanen M, Lindén J, Garrels T, Pekkala S, Lahti L. Xylo-Oligosaccharides in Prevention of Hepatic Steatosis and Adipose Tissue Inflammation: Associating Taxonomic and Metabolomic Patterns in Fecal Microbiomes with Biclustering. Int J Environ Res Public Health 2021;18:4049. [PMID: 33921370 DOI: 10.3390/ijerph18084049] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
176 Ma C, Zhang Q, Greten TF. MDSCs in liver cancer: A critical tumor-promoting player and a potential therapeutic target. Cell Immunol 2021;361:104295. [PMID: 33508529 DOI: 10.1016/j.cellimm.2021.104295] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
177 Tao W, Sun W, Liu L, Wang G, Xiao Z, Pei X, Wang M. Chitosan Oligosaccharide Attenuates Nonalcoholic Fatty Liver Disease Induced by High Fat Diet through Reducing Lipid Accumulation, Inflammation and Oxidative Stress in C57BL/6 Mice. Mar Drugs 2019;17:E645. [PMID: 31744059 DOI: 10.3390/md17110645] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
178 Gil-Gómez A, Brescia P, Rescigno M, Romero-Gómez M. Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers. Semin Liver Dis 2021;41:191-205. [PMID: 34107545 DOI: 10.1055/s-0041-1723752] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
179 Dong Z, He F, Yan X, Xing Y, Lei Y, Gao J, He M, Li D, Bai L, Yuan Z, Y-J Shyy J. Hepatic Reduction in Cholesterol 25-Hydroxylase Aggravates Diet-Induced Steatosis. Cell Mol Gastroenterol Hepatol 2022:S2352-345X(21)00271-X. [PMID: 34990887 DOI: 10.1016/j.jcmgh.2021.12.018] [Reference Citation Analysis]
180 Lopresti MW, Cui W, Abernathy B, Fredrickson G, Barrow F, Desai AS, Revelo XS, Mashek D. Hepatic Lysosomal Acid Lipase Overexpression Worsens Hepatic Inflammation in Mice Fed a Western Diet. J Lipid Res 2021;:100133. [PMID: 34624333 DOI: 10.1016/j.jlr.2021.100133] [Reference Citation Analysis]
181 Vila-Bedmar R, Cruces-Sande M, Arcones AC, Willemen HLDM, Prieto P, Moreno-Indias I, Díaz-Rodríguez D, Francisco S, Jaén RI, Gutiérrez-Repiso C, Heijnen CJ, Boscá L, Fresno M, Kavelaars A, Mayor F Jr, Murga C. GRK2 levels in myeloid cells modulate adipose-liver crosstalk in high fat diet-induced obesity. Cell Mol Life Sci 2020;77:4957-76. [PMID: 31927610 DOI: 10.1007/s00018-019-03442-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
182 Ichikawa H, Imoto H, Tanaka N, Fujishima F, Tsuchiya T, Watanabe K, Aoki T, Kohyama A, Morikawa T, Ohnuma S, Naitoh T, Kamei T, Unno M. The role of bilio-pancreatic limb in nonalcoholic steatohepatitis improvement after duodenal-jejunal bypass in rats. Surgery 2021:S0039-6060(21)00679-6. [PMID: 34389163 DOI: 10.1016/j.surg.2021.07.003] [Reference Citation Analysis]
183 Dalmas E. Role of innate immune cells in metabolism: from physiology to type 2 diabetes. Semin Immunopathol 2019;41:531-45. [DOI: 10.1007/s00281-019-00736-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
184 Alharthi J, Latchoumanin O, George J, Eslam M. Macrophages in metabolic associated fatty liver disease. World J Gastroenterol 2020; 26(16): 1861-1878 [PMID: 32390698 DOI: 10.3748/wjg.v26.i16.1861] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
185 Wang Q, Li D, Zhu J, Zhang M, Zhang H, Cao G, Zhu L, Shi Q, Hao J, Wen Q, Liu Z, Yang H, Yin Z. Perforin Acts as an Immune Regulator to Prevent the Progression of NAFLD. Front Immunol 2020;11:846. [PMID: 32528465 DOI: 10.3389/fimmu.2020.00846] [Reference Citation Analysis]
186 Kawamura T, Tanaka H, Tachibana R, Yoshikawa K, Maki S, Toriyabe K, Takeuchi H, Katsuragi S, Tanaka K, Ikeda T. Maternal tadalafil therapy for fetal growth restriction prevents non-alcoholic fatty liver disease and adipocyte hypertrophy in the offspring. Sci Rep 2021;11:1186. [PMID: 33441894 DOI: 10.1038/s41598-020-80643-0] [Reference Citation Analysis]
187 Hong W, Li S, Cai Y, Zhang T, Yang Q, He B, Yu J, Chen Z. The Target MicroRNAs and Potential Underlying Mechanisms of Yiqi-Bushen-Tiaozhi Recipe against-Non-Alcoholic Steatohepatitis. Front Pharmacol 2020;11:529553. [PMID: 33281601 DOI: 10.3389/fphar.2020.529553] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
188 Jiang ZY, Zhou Y, Zhou L, Li SW, Wang BM. Identification of Key Genes and Immune Infiltrate in Nonalcoholic Steatohepatitis: A Bioinformatic Analysis. Biomed Res Int 2021;2021:7561645. [PMID: 34552988 DOI: 10.1155/2021/7561645] [Reference Citation Analysis]
189 Zhang AMY, Wellberg EA, Kopp JL, Johnson JD. Hyperinsulinemia in Obesity, Inflammation, and Cancer. Diabetes Metab J 2021;45:285-311. [PMID: 33775061 DOI: 10.4093/dmj.2020.0250] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
190 Hirsova P, Bohm F, Dohnalkova E, Nozickova B, Heikenwalder M, Gores GJ, Weber A. Hepatocyte apoptosis is tumor promoting in murine nonalcoholic steatohepatitis. Cell Death Dis. 2020;11:80. [PMID: 32015322 DOI: 10.1038/s41419-020-2283-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
191 Yan S. Role of TFEB in Autophagy and the Pathogenesis of Liver Diseases. Biomolecules 2022;12:672. [DOI: 10.3390/biom12050672] [Reference Citation Analysis]
192 Luque-Martin R, Angell DC, Kalxdorf M, Bernard S, Thompson W, Eberl HC, Ashby C, Freudenberg J, Sharp C, Van den Bossche J, de Jonge WJ, Rioja I, Prinjha RK, Neele AE, de Winther MPJ, Mander PK. IFN-γ Drives Human Monocyte Differentiation into Highly Proinflammatory Macrophages That Resemble a Phenotype Relevant to Psoriasis. J Immunol 2021:ji2001310. [PMID: 34233910 DOI: 10.4049/jimmunol.2001310] [Reference Citation Analysis]
193 Kim DH, Bang E, Arulkumar R, Ha S, Chung KW, Park MH, Choi YJ, Yu BP, Chung HY. Senoinflammation: A major mediator underlying age-related metabolic dysregulation. Exp Gerontol 2020;134:110891. [PMID: 32114077 DOI: 10.1016/j.exger.2020.110891] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
194 Zheng Y, Fang D, Huang C, Zhao L, Gan L, Chen Y, Liu F. Gentiana scabra Restrains Hepatic Pro-Inflammatory Macrophages to Ameliorate Non-Alcoholic Fatty Liver Disease. Front Pharmacol 2022;12:816032. [DOI: 10.3389/fphar.2021.816032] [Reference Citation Analysis]
195 Ohtani N, Kawada N. Role of the Gut-Liver Axis in Liver Inflammation, Fibrosis, and Cancer: A Special Focus on the Gut Microbiota Relationship. Hepatol Commun. 2019;3:456-470. [PMID: 30976737 DOI: 10.1002/hep4.1331] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
196 Kunst RF, Niemeijer M, van der Laan LJW, Spee B, van de Graaf SFJ. From fatty hepatocytes to impaired bile flow: Matching model systems for liver biology and disease. Biochem Pharmacol 2020;180:114173. [PMID: 32717228 DOI: 10.1016/j.bcp.2020.114173] [Reference Citation Analysis]
197 Wang Z, Wang M, Yang R, Zhao Z, Xin F, Li Y, Ren T, Fan J. Ammonia Scavenger Restores Liver and Muscle Injury in a Mouse Model of Non-alcoholic Steatohepatitis With Sarcopenic Obesity. Front Nutr 2022;9:808497. [DOI: 10.3389/fnut.2022.808497] [Reference Citation Analysis]
198 Fraser DA, Wang X, Lund J, Nikolić N, Iruarrizaga-Lejarreta M, Skjaeret T, Alonso C, Kastelein JJP, Rustan AC, Kim YO, Schuppan D. A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH. J Hepatol 2021:S0168-8278(21)02244-3. [PMID: 34915054 DOI: 10.1016/j.jhep.2021.12.004] [Reference Citation Analysis]
199 Luci C, Vieira E, Bourinet M, Rousseau D, Bonnafous S, Patouraux S, Lefevre L, Larbret F, Prod'homme V, Iannelli A, Tran A, Anty R, Bailly-Maitre B, Deckert M, Gual P. SYK-3BP2 Pathway Activity in Parenchymal and Myeloid Cells Is a Key Pathogenic Factor in Metabolic Steatohepatitis. Cell Mol Gastroenterol Hepatol 2021;13:173-91. [PMID: 34411785 DOI: 10.1016/j.jcmgh.2021.08.004] [Reference Citation Analysis]
200 van der Zande HJP, Zawistowska-Deniziak A, Guigas B. Immune Regulation of Metabolic Homeostasis by Helminths and Their Molecules. Trends Parasitol 2019;35:795-808. [PMID: 31492623 DOI: 10.1016/j.pt.2019.07.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
201 Toita R, Shimizu E, Murata M, Kang J. Protective and healing effects of apoptotic mimic-induced M2-like macrophage polarization on pressure ulcers in young and middle-aged mice. Journal of Controlled Release 2021;330:705-14. [DOI: 10.1016/j.jconrel.2020.12.052] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
202 Wang F, Zhang X, Liu W, Zhou Y, Wei W, Liu D, Wong CC, Sung JJY, Yu J. Activated Natural Killer Cell Promotes Nonalcoholic Steatohepatitis Through Mediating JAK/STAT Pathway. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00186-7. [PMID: 34506952 DOI: 10.1016/j.jcmgh.2021.08.019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
203 Rabut C, Wu D, Ling B, Jin Z, Malounda D, Shapiro MG. Ultrafast amplitude modulation for molecular and hemodynamic ultrasound imaging. Appl Phys Lett 2021;118:244102. [PMID: 34176950 DOI: 10.1063/5.0050807] [Reference Citation Analysis]
204 Guan Y, Xu Y, Su H, Sun X, Li Y, Wang T. Effect of serum vitamin D on metabolic associated fatty liver disease: a large population-based study. Scand J Gastroenterol 2022;:1-10. [PMID: 35170370 DOI: 10.1080/00365521.2022.2039284] [Reference Citation Analysis]
205 Bekkering S, Saner C, Riksen NP, Netea MG, Sabin MA, Saffery R, Stienstra R, Burgner DP. Trained Immunity: Linking Obesity and Cardiovascular Disease across the Life-Course? Trends Endocrinol Metab 2020;31:378-89. [PMID: 32305098 DOI: 10.1016/j.tem.2020.01.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
206 Wang SW, Lan T, Sheng H, Zheng F, Lei MK, Wang LX, Chen HF, Xu CY, Zhang F. Nobiletin Alleviates Non-alcoholic Steatohepatitis in MCD-Induced Mice by Regulating Macrophage Polarization. Front Physiol 2021;12:687744. [PMID: 34093242 DOI: 10.3389/fphys.2021.687744] [Reference Citation Analysis]
207 Li Q, Feng H, Wang H, Wang Y, Mou W, Xu G, Zhang P, Li R, Shi W, Wang Z, Fang Z, Ren L, Wang Y, Lin L, Hou X, Dai W, Li Z, Wei Z, Liu T, Wang J, Guo Y, Li P, Zhao X, Zhan X, Xiao X, Bai Z. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7-NLRP3 interaction. EMBO Rep 2021;:e53499. [PMID: 34882936 DOI: 10.15252/embr.202153499] [Reference Citation Analysis]
208 Kanda T, Goto T, Hirotsu Y, Masuzaki R, Moriyama M, Omata M. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E1525. [PMID: 32102237 DOI: 10.3390/ijms21041525] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
209 Huang X, Xu J, Hu Y, Huang K, Luo Y, He X. Broccoli ameliorate NAFLD by increasing lipolysis and promoting liver macrophages polarize toward M2-type. Journal of Functional Foods 2022;89:104898. [DOI: 10.1016/j.jff.2021.104898] [Reference Citation Analysis]
210 Goodus MT, McTigue DM. Hepatic dysfunction after spinal cord injury: A vicious cycle of central and peripheral pathology? Exp Neurol 2020;325:113160. [PMID: 31863731 DOI: 10.1016/j.expneurol.2019.113160] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
211 Ziolkowska S, Binienda A, Jabłkowski M, Szemraj J, Czarny P. The Interplay between Insulin Resistance, Inflammation, Oxidative Stress, Base Excision Repair and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:11128. [PMID: 34681787 DOI: 10.3390/ijms222011128] [Reference Citation Analysis]
212 Wang P, Ni M, Tian Y, Wang H, Qiu J, You W, Wei S, Shi Y, Zhou J, Cheng F, Rao J, Lu L. Myeloid Nrf2 deficiency aggravates non-alcoholic steatohepatitis progression by regulating YAP-mediated NLRP3 inflammasome signaling. iScience 2021;24:102427. [PMID: 34041450 DOI: 10.1016/j.isci.2021.102427] [Reference Citation Analysis]
213 Elsayed HRH, El-Nablaway M, Othman BH, Abdalla AM, El Nashar EM, Abd-Elmonem MM, El-Gamal R. Can Dasatinib Ameliorate the Hepatic changes, Induced by Long Term Western Diet, in Mice? Ann Anat 2021;234:151626. [PMID: 33144268 DOI: 10.1016/j.aanat.2020.151626] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
214 Rada P, González-Rodríguez Á, García-Monzón C, Valverde ÁM. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver? Cell Death Dis 2020;11:802. [PMID: 32978374 DOI: 10.1038/s41419-020-03003-w] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 13.0] [Reference Citation Analysis]
215 Hirsova P, Bamidele AO, Wang H, Povero D, Revelo XS. Emerging Roles of T Cells in the Pathogenesis of Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma. Front Endocrinol (Lausanne) 2021;12:760860. [PMID: 34777255 DOI: 10.3389/fendo.2021.760860] [Reference Citation Analysis]
216 Caputo M, Kurhe Y, Kumari S, Cansby E, Amrutkar M, Scandalis E, Booten SL, Ståhlman M, Borén J, Marschall HU, Aghajan M, Mahlapuu M. Silencing of STE20-type kinase MST3 in mice with antisense oligonucleotide treatment ameliorates diet-induced nonalcoholic fatty liver disease. FASEB J 2021;35:e21567. [PMID: 33891332 DOI: 10.1096/fj.202002671RR] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
217 Lin SZ, Fan JG. Peripheral immune cells in NAFLD patients: A spyhole to disease progression. EBioMedicine 2021;75:103768. [PMID: 34929490 DOI: 10.1016/j.ebiom.2021.103768] [Reference Citation Analysis]
218 Huang H, Zhang X, Zhang C, Chen H, Ling Q, Zheng S. The time-dependent shift in the hepatic graft and recipient macrophage pool following liver transplantation. Cell Mol Immunol. 2020;17:412-414. [PMID: 31243358 DOI: 10.1038/s41423-019-0253-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
219 Albuquerque-Souza E, Sahingur SE. Periodontitis, chronic liver diseases, and the emerging oral-gut-liver axis. Periodontol 2000 2022. [PMID: 35244954 DOI: 10.1111/prd.12427] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
220 Yan K, Zhang P, Jin J, Chen X, Guan H, Li Y, Li H. Integrative analyses of hub genes and their association with immune infiltration in adipose tissue, liver tissue and skeletal muscle of obese patients after bariatric surgery. Adipocyte 2022;11:190-201. [PMID: 35412419 DOI: 10.1080/21623945.2022.2060059] [Reference Citation Analysis]
221 Li L, Chen L, Wang H, Li P, Wang D, Zhang W, Mi L, Lin F, Qin Y, Zhou Y. Clinical correlation between coagulation disorders and sepsis in patients with liver failure. Clin Hemorheol Microcirc 2021. [PMID: 34719481 DOI: 10.3233/CH-211113] [Reference Citation Analysis]
222 Xu G, Wang YM, Ying MM, Chen SD, Li ZR, Ma HL, Zheng MH, Wu J, Ding C. Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis. Clin Mol Hepatol 2021;27:329-45. [PMID: 33465844 DOI: 10.3350/cmh.2020.0261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
223 Luci C, Vieira E, Perchet T, Gual P, Golub R. Natural Killer Cells and Type 1 Innate Lymphoid Cells Are New Actors in Non-alcoholic Fatty Liver Disease. Front Immunol 2019;10:1192. [PMID: 31191550 DOI: 10.3389/fimmu.2019.01192] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
224 Di Guglielmo MD, Perito ER. To Juice or Not to Juice: Fatty Liver Repercussions for Infants. Hepatology 2021;73:483-5. [PMID: 33368446 DOI: 10.1002/hep.31696] [Reference Citation Analysis]
225 Vogel A, Brunner JS, Hajto A, Sharif O, Schabbauer G. Lipid scavenging macrophages and inflammation. Biochim Biophys Acta Mol Cell Biol Lipids 2022;1867:159066. [PMID: 34626791 DOI: 10.1016/j.bbalip.2021.159066] [Reference Citation Analysis]
226 Cheon SY, Cho K. Lipid metabolism, inflammation, and foam cell formation in health and metabolic disorders: targeting mTORC1. J Mol Med (Berl) 2021. [PMID: 34312684 DOI: 10.1007/s00109-021-02117-8] [Reference Citation Analysis]
227 Kazankov K, Rosso C, Younes R, Armandi A, Hagström H, Møller HJ, Stål P, Bugianesi E, Grønbæk H. Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease. Front Med (Lausanne) 2020;7:616212. [PMID: 33392234 DOI: 10.3389/fmed.2020.616212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
228 Shen M, Shen Y, Fan X, Men R, Ye T, Yang L. Roles of Macrophages and Exosomes in Liver Diseases. Front Med (Lausanne) 2020;7:583691. [PMID: 33072790 DOI: 10.3389/fmed.2020.583691] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
229 He W, Huang C, Zhang X, Wang D, Chen Y, Zhao Y, Li X. Identification of transcriptomic signatures and crucial pathways involved in non-alcoholic steatohepatitis. Endocrine 2021;73:52-64. [PMID: 33837926 DOI: 10.1007/s12020-021-02716-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
230 Singanayagam A, Triantafyllou E. Macrophages in Chronic Liver Failure: Diversity, Plasticity and Therapeutic Targeting. Front Immunol 2021;12:661182. [PMID: 33868313 DOI: 10.3389/fimmu.2021.661182] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
231 de Oliveira FL, Panera N, De Stefanis C, Mosca A, D'Oria V, Crudele A, De Vito R, Nobili V, Alisi A. The Number of Liver Galectin-3 Positive Cells Is Dually Correlated with NAFLD Severity in Children. Int J Mol Sci 2019;20:E3460. [PMID: 31337151 DOI: 10.3390/ijms20143460] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
232 Wu SJ, Huang WC, Yu MC, Chen YL, Shen SC, Yeh KW, Liou CJ. Tomatidine ameliorates obesity-induced nonalcoholic fatty liver disease in mice. J Nutr Biochem 2021;91:108602. [PMID: 33548473 DOI: 10.1016/j.jnutbio.2021.108602] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
233 Kjær MB, George J, Kazankov K, Grønbæk H. Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy? Expert Rev Gastroenterol Hepatol 2021;15:51-64. [PMID: 32878486 DOI: 10.1080/17474124.2020.1817740] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
234 Gluais-Dagorn P, Foretz M, Steinberg GR, Batchuluun B, Zawistowska-Deniziak A, Lambooij JM, Guigas B, Carling D, Monternier PA, Moller DE, Bolze S, Hallakou-Bozec S. Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis. Hepatol Commun 2021. [PMID: 34494384 DOI: 10.1002/hep4.1799] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
235 Gómez-Hurtado I, Gallego-Durán R, Zapater P, Ampuero J, Aller R, Crespo J, Arias-Loste M, García-Monzón C, Bellot P, González-Rodríguez Á, Juanola O, Romero-Gómez M, Francés R. Bacterial antigen translocation and age as BMI-independent contributing factors on systemic inflammation in NAFLD patients. Liver Int 2020;40:2182-93. [PMID: 32559006 DOI: 10.1111/liv.14571] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
236 Maliakkal BJ. Pathogenesis of non-alcoholic fatty liver disease and implications on cardiovascular outcomes in liver transplantation. Transl Gastroenterol Hepatol 2020;5:36. [PMID: 32632387 DOI: 10.21037/tgh.2019.12.02] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
237 Filipovic B, Lukic S, Mijac D, Marjanovic-Haljilji M, Vojnovic M, Bogdanovic J, Glisic T, Filipovic N, Al Kiswani J, Djokovic A, Kapor S, Kapor S, Bukumiric Z, Starcevic A. The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:13219. [PMID: 34948020 DOI: 10.3390/ijms222413219] [Reference Citation Analysis]
238 Suurmond CE, Lasli S, van den Dolder FW, Ung A, Kim HJ, Bandaru P, Lee K, Cho HJ, Ahadian S, Ashammakhi N, Dokmeci MR, Lee J, Khademhosseini A. In Vitro Human Liver Model of Nonalcoholic Steatohepatitis by Coculturing Hepatocytes, Endothelial Cells, and Kupffer Cells. Adv Healthc Mater 2019;8:e1901379. [PMID: 31746151 DOI: 10.1002/adhm.201901379] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
239 Guo WR, Liu J, Cheng LD, Liu ZY, Zheng XB, Liang H, Xu F. Metformin Alleviates Steatohepatitis in Diet-Induced Obese Mice in a SIRT1-Dependent Way. Front Pharmacol 2021;12:704112. [PMID: 34483906 DOI: 10.3389/fphar.2021.704112] [Reference Citation Analysis]
240 Chen H, Zhou S, Zhu M, Wang B, Chen W, Zheng L, Wang M, Feng W. Gold Nanoparticles Modified With Polyethyleneimine Disturbed the Activity of Drug-Metabolic Enzymes and Induced Inflammation-Mediated Liver Injury in Mice. Front Pharmacol 2021;12:706791. [PMID: 34335268 DOI: 10.3389/fphar.2021.706791] [Reference Citation Analysis]
241 Chen S, Cai X, Liu Y, Shen Y, Guillot A, Tacke F, Tang L, Liu H. The macrophage-associated microRNA-4715-3p / Gasdermin D axis potentially indicates fibrosis progression in nonalcoholic fatty liver disease: evidence from transcriptome and biological data. Bioengineered 2022;13:11740-51. [PMID: 35521691 DOI: 10.1080/21655979.2022.2072602] [Reference Citation Analysis]
242 Sulen A. Liver Macrophage Isolation by Flow Cytometry Sorting. Methods Mol Biol 2020;2164:15-20. [PMID: 32607879 DOI: 10.1007/978-1-0716-0704-6_3] [Reference Citation Analysis]
243 Shao J, Li S, Liu Y, Zheng M. Extracellular vesicles participate in macrophage-involved immune responses under liver diseases. Life Sci 2020;240:117094. [PMID: 31760101 DOI: 10.1016/j.lfs.2019.117094] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
244 Furuta K, Guo Q, Pavelko KD, Lee JH, Robertson KD, Nakao Y, Melek J, Shah VH, Hirsova P, Ibrahim SH. Lipid-induced endothelial vascular cell adhesion molecule 1 promotes nonalcoholic steatohepatitis pathogenesis. J Clin Invest 2021;131:143690. [PMID: 33476308 DOI: 10.1172/JCI143690] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
245 Tillman EJ, Rolph T. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. Front Endocrinol (Lausanne) 2020;11:601290. [PMID: 33381084 DOI: 10.3389/fendo.2020.601290] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
246 Qi X, Yang M, Stenberg J, Dey R, Fogwe L, Alam MS, Kimchi ET, Staveley-O'Carroll KF, Li G. Gut microbiota mediated molecular events and therapy in liver diseases. World J Gastroenterol 2020; 26(48): 7603-7618 [PMID: 33505139 DOI: 10.3748/wjg.v26.i48.7603] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
247 Joshi SS, Davis RP, Ma MM, Tam E, Cooper CL, Ramji A, Kelly EM, Jayakumar S, Swain MG, Jenne CN, Coffin CS. Reduced immune responses to hepatitis B primary vaccination in obese individuals with nonalcoholic fatty liver disease (NAFLD). NPJ Vaccines 2021;6:9. [PMID: 33431890 DOI: 10.1038/s41541-020-00266-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
248 Maeda H, Hosomi R, Yokoyama T, Ikeda Y, Nishimoto A, Tanaka G, Shimono T, Kanda S, Nishiyama T, Yoshida M, Fukunaga K. Dietary Alaska pollock protein attenuates liver steatosis and alters gut microbiota in leptin-deficient ob/ob mice. Journal of Functional Foods 2020;75:104266. [DOI: 10.1016/j.jff.2020.104266] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
249 Du HJ, Zhao SX, Zhao W, Fu N, Li WC, Qin XJ, Zhang YG, Nan YM, Zhao JM. Hepatic Macrophage activation and the LPS pathway in patients with different degrees of severity and histopathological patterns of drug induced liver injury. Histol Histopathol 2021;36:653-62. [PMID: 33870482 DOI: 10.14670/HH-18-340] [Reference Citation Analysis]
250 Yi Y. Regulatory Roles of Caspase-11 Non-Canonical Inflammasome in Inflammatory Liver Diseases. IJMS 2022;23:4986. [DOI: 10.3390/ijms23094986] [Reference Citation Analysis]
251 Gao T, Liu T, Ko CJ, Zhang L, Joo D, Xie X, Zhu L, Li Y, Cheng X, Sun SC. Myeloid cell TBK1 restricts inflammatory responses. Proc Natl Acad Sci U S A 2022;119:e2107742119. [PMID: 35074921 DOI: 10.1073/pnas.2107742119] [Reference Citation Analysis]
252 Nilsson J, Hörnberg M, Schmidt-Christensen A, Linde K, Nilsson M, Carlus M, Erttmann SF, Mayans S, Holmberg D. NKT cells promote both type 1 and type 2 inflammatory responses in a mouse model of liver fibrosis. Sci Rep 2020;10:21778. [PMID: 33311540 DOI: 10.1038/s41598-020-78688-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
253 Wu H, Ni X, Xu Q, Wang Q, Li X, Hua J. Regulation of lipid‐induced macrophage polarization through modulating peroxisome proliferator‐activated receptor‐gamma activity affects hepatic lipid metabolism via a Toll‐like receptor 4/NF‐κB signaling pathway. Journal of Gastroenterology and Hepatology 2020;35:1998-2008. [DOI: 10.1111/jgh.15025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]